At the time of writing, Dyne Therapeutics Inc [DYN] stock is trading at $35.38, up 27.82%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DYN shares have gain 32.91% over the last week, with a monthly amount glided 48.28%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on April 30, 2024, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $40. Previously, H.C. Wainwright started tracking the stock with Buy rating on February 20, 2024, and set its price target to $36. On February 27, 2023, upgrade upgraded it’s rating to Strong Buy and revised its price target to $27 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $34 on February 15, 2023. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on January 26, 2023. Chardan Capital Markets started tracking with a Buy rating for this stock on July 20, 2022, and assigned it a price target of $17. In a note dated July 12, 2022, Raymond James initiated an Outperform rating and provided a target price of $15 on this stock.
For the past year, the stock price of Dyne Therapeutics Inc fluctuated between $6.40 and $30.27. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $35.38 at the most recent close of the market. An investor can expect a potential drop of -3.9% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -70.18%, Pretax Profit Margin comes in at -67.95%, and Net Profit Margin reading is -67.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.11 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.11 points at the first support level, and at 28.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.16, and for the 2nd resistance point, it is at 38.93.
Ratios To Look Out For
It is important to note that Dyne Therapeutics Inc [NASDAQ:DYN] has a current ratio of 21.83. Further, the Quick Ratio stands at 21.83, while the Cash Ratio is 12.16.
Transactions by insiders
Recent insider trading involved McNeill Jonathan, Chief Business Officer, that happened on May 16 ’24 when 2774.0 shares were sold. Chief Operating Officer, HIGH SUSANNA GATTI completed a deal on May 16 ’24 to sell 2738.0 shares. Meanwhile, Chief Scientific Officer Beskrovnaya Oxana sold 2705.0 shares on May 16 ’24.
